Cross-Linked Hemoglobin Blood Substitute Without Borohydride
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemoglobin-based blood substitute manufacturing methodologies are uneconomical, complex, and involve impractical chemical reactants like sodium borohydride, leading to safety concerns and inefficiencies, while alternative oxygen carriers like perfluorocarbons have low oxygen solubility and stability issues.
Innovation Solution
A method involving low purity erythrocyte protein fractions are cross-linked using polyaldehydes to form cross-linked proteins, avoiding sodium borohydride and enabling efficient production of hemoglobin-based blood substitutes with improved oxygen delivery characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly purified hemoglobin preparations are manufactured using existing methodologies, then oxygen delivery characteristics are achieved, but manufacturing complexity and costs increase substantially
Solution Approach 1:
The patent extracts and removes stroma lipids from hemoglobin preparations through a series of purification steps including centrifugation, filtration, and solvent extraction. This extraction of harmful components allows the use of less complex manufacturing processes while maintaining oxygen delivery characteristics, directly resolving the contradiction between reliability and manufacturing complexity.
Solution Approach 2:
The patent changes the purity parameter requirements from 'highly purified' to 'moderately purified' by modifying the manufacturing process parameters. Instead of requiring complete removal of all impurities, the process accepts controlled levels of certain components while removing specific harmful stroma lipids. This parameter change reduces manufacturing complexity while preserving essential oxygen delivery function.
2Manufacturing precision
If sodium borohydride is used for hemoglobin polymerization, then cross-linked hemoglobin products are formed, but safety concerns arise due to hydrogen gas release
Solution Approach 1:
The patent introduces glutaraldehyde as an intermediary cross-linking agent that mediates the polymerization of hemoglobin molecules. Instead of using sodium borohydride which directly releases hydrogen gas, glutaraldehyde serves as a safe intermediary that forms cross-links between hemoglobin molecules through aldehyde-amine condensation reactions, eliminating the hydrogen gas safety hazard while achieving the desired polymerization.
Solution Approach 2:
The patent substitutes the chemical mechanism of sodium borohydride reduction with a different chemical mechanism using glutaraldehyde cross-linking. The reduction-based polymerization method is replaced with a condensation-based cross-linking method, which achieves similar polymerization outcomes without the harmful hydrogen gas byproduct.
3Object-affected harmful factors
If stroma lipids are removed from hemoglobin preparations, then nephrotoxicity is reduced, but oxygen delivery characteristics and vascular half-life are significantly reduced
Solution Approach 1:
The patent applies local quality by selectively removing specific stroma lipid components that cause nephrotoxicity while preserving other components that are essential for oxygen delivery and vascular stability. Rather than complete lipid removal, the process targets specific harmful lipids through selective extraction methods, maintaining local functional quality while eliminating toxic effects.
Solution Approach 2:
The patent creates a composite hemoglobin preparation that combines purified hemoglobin with selected stabilizing components. By forming a composite structure that includes hemoglobin, controlled amounts of certain proteins, and specific lipids, the preparation achieves both reduced nephrotoxicity and maintained oxygen delivery characteristics. The composite formulation balances toxicological safety with functional performance.
4Reliability
If elaborate safety conditions are implemented to control hydrogen gas, then manufacturing safety is improved, but manufacturing efficiency and economy are significantly impeded
Solution Approach 1:
The patent converts the harmful aspect of chemical cross-linking (hydrogen gas release) into a beneficial situation by selecting a cross-linking method that inherently avoids the hazard. Glutaraldehyde cross-linking proceeds without significant gas evolution, transforming a potentially dangerous process into a safe one. This eliminates the need for elaborate safety infrastructure while maintaining manufacturing efficiency and economy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of stable, efficient, and economical hemoglobin-based blood substitutes with enhanced oxygen delivery capabilities, reducing manufacturing complexity and safety risks.
Implementation Method 1
contacting the low purity erythrocyte protein fraction with a reactant capable of chemically modifying the proteins in the protein fraction
Implementation Method 2
the reactant thereby mediating the formation of cross-linked proteins comprising intermolecular cross-linkages between the hemoglobin protein molecules
Data Source
AI summary
Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.